Sartorius Acquires Cellca
News Jul 03, 2015
Cellca’s major customers are biopharmaceutical companies as well as biosimilar firms that do not or only partly conduct their process development in their in-house facilities. Through this acquisition, Sartorius Stedim Biotech is further expanding its service offering for process development, according to Reinhard Vogt, a member of the SSB executive committee for marketing and sales, who added that SSB has already strengthened this segment by its two recent acquisitions of BioOutsource and TAP Biosystems.
“Together with our single-use products, media and testing services, we are creating an attractive package, above all for young biopharmaceutical companies that need robust processes for the manufacture of their biologics," he explained
Founded in 2005, Cellca has a staff of 30 employees and generated sales revenue of approximately €6 million (about $6.65 million) in 2014.
BIA Separations appoints Pete Gagnon as Chief Scientific OfficerNews
Appointment will drive new product and applications development.READ MORE
Heart-on-a-chip Manufactured More Efficiently to Speed Up Drug TestingNews
Testing new clinical drugs' effect on heart tissue could become quicker and more straightforward, thanks to new research from Harvard University.
The study, sets out a new, faster method for manufacturing a 'heart-on-a-chip', which can be used to test the reaction of heart tissue to external stimuli.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE